My Cart [ 0 ]
Home > Antibodies > Anti-Mouse Antibodies (In Vivo) > Anti-Mouse CD8a Monoclonal Antibodies

Anti-Mouse CD8a Monoclonal Antibodies

CD8 alpha, T-cell surface glycoprotein CD8 alpha chain, CD_antigen CD8a

Catalog No. Product Name Size List Price (US$) Quantity
PA007167.m2a In Vivo Grade Recombinant Anti-Mouse CD8a Monoclonal Antibody (Clone 2.43), Mouse IgG2a Kappa 1 mg 150.00
PA007167.m2a In Vivo Grade Recombinant Anti-Mouse CD8a Monoclonal Antibody (Clone 2.43), Mouse IgG2a Kappa 5 mg 350.00
PA007167.m2a In Vivo Grade Recombinant Anti-Mouse CD8a Monoclonal Antibody (Clone 2.43), Mouse IgG2a Kappa 25 mg 900.00
PA007167.r2b In Vivo Grade Recombinant Anti-Mouse CD8a Monoclonal Antibody (Clone 2.43), Rat IgG2b Kappa 1 mg 150.00
PA007167.r2b In Vivo Grade Recombinant Anti-Mouse CD8a Monoclonal Antibody (Clone 2.43), Rat IgG2b Kappa 5 mg 350.00
PA007167.r2b In Vivo Grade Recombinant Anti-Mouse CD8a Monoclonal Antibody (Clone 2.43), Rat IgG2b Kappa 25 mg 900.00
Description

Background of Recombinant Anti-Mouse CD8a Monoclonal Antibody, Rat IgG2b Kappa

The rat anti-mouse CD8a monoclonal antibody 2.43  (rat IgG2b kappa) reacts with the mouse CD8a protein (T-cell surface glycoprotein CD8 alpha chain) encoded by the mouse CD8A gene that encodes the CD8a chain of the dimeric CD8 protein. The mouse CD8 protein is primarily responsible for cell-mediated immune defense and T-cell development. CD8A has been widely reported as a potential prognosis and diagnostic marker for several diseases, such as inflammatory disorders and tumors. It was shown that the anti-mouse CD8a rat monoclonal antibody (clone number: 2.43) can be used for depleting activity in vivo.

Our recombinant 2.43 antibodies have a part (variable regions) or complete amino acid sequences of the rat anti-mouse CD8a monoclonal antibody (hybridoma clone name or number: 2.43).

PA007167.m2a: In Vivo Grade Recombinant Anti-Mouse CD8a Mouse IgG2a Kappa Monoclonal Antibody

The in vivo grade recombinant anti-mouse CD8a mouse IgG2a monoclonal antibody was produced in mammalian cells.
Specificity: CD8a.
Clone: 2.43.
Isotype: mouse IgG2a, kappa.
Applications: Western blot, immunohistochemistry (IHC), Flow Cytometry (FC), and in vivo CD8+ T cell depletion.
Formulation: 0.2 μM filtered solution of 1x PBS.
Purity: >95% by SDS-PAGE under reducing conditions.
Endotoxin Level: Less than 1 EU/mg of protein as determined by LAL method.

PA007167.r2b: In Vivo Grade Recombinant Anti-Mouse CD8a Rat IgG2b Kappa Monoclonal Antibody

The in vivo grade recombinant anti-mouse CD8a rat IgG2b monoclonal antibody was produced in mammalian cells.
Specificity: CD8a.
Clone: 2.43.
Isotype: rat IgG2b, kappa.
Applications: Western blot, immunohistochemistry (IHC), Flow Cytometry (FC), and in vivo CD8+ T cell depletion.
Formulation: 0.2 μM filtered solution of 1x PBS.
Purity: >95% by SDS-PAGE under reducing conditions.
Endotoxin Level: Less than 1 EU/mg of protein as determined by LAL method.

Shipping: The in vivo grade recombinant anti-mouse CD8a antibodies (clone of 2.43) are shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
1 month from date of receipt, 2 to 8°C as supplied.
3 months from date of receipt, -20°C to -70°C as supplied.

References of anti-mouse CD8a antibody (2.43):

1?Circulating neutralizing antibodies and SARS-CoV-2 variant replication following postvaccination infections.
Garcia-Knight, M. A., et al. JCI Insight. 2025 Mar;10(5):e185953. doi: 10.1172/jci.insight.185953. PMID: 40059831
Per log10 increase in Delta-targeting baseline NAb IC50, maximum viral load was reduced ?2.43 (2.43 antibody) (95% CI: ?3.76, ?1.11) log10 nucleocapsid copies, and infectious viral shedding was reduced ?2.79 (95% CI: ?4.99, ?0.60) days. ...Our findings show that, following PVI (in people vaccinated with ancestral spike antigens), higher baseline NAb titers are associated with accelerated viral clearance dynamics following infections with Delta variants, and we provide robust estimations to help quantify this effect. ...This suggests that NAbs generated through first-generation vaccines are limited in their ability to target conserved epitopes in the spike protein of Omicron variants and support the use of booster vaccination with updated antigens that may further broaden the NAb response. ...It remains to be seen whether enhancing baseline neutralizing antibody (anti-mouse CD8a antibody) (NAb) titers through updated vaccine antigens can reestablish the correlation with viral shedding outcomes in primary viral infections (PVI) involving current circulating variants. ...Baseline NAb titers targeting the infecting variant for each participant (except those with BA.5 infections for which response against BA.2 are shown) were higher in those who had received vaccine booster doses compared with those who received a primary series (P < 0.05).
Tags: anti-mouse CD8a antibody; 2.43 antibody

2?Combination of omalizumab with allergen immunotherapy versus immunotherapy alone for allergic diseases: A meta-analysis of randomized controlled trials.
Zhang, Y.-Y., et al. International Forum of Allergy & Rhinology. 2024 Apr;14(4):794-806. doi: 10.1002/alr.23268. PMID: 37715592
According to a pooled analysis, omalizumab + AIT significantly increased the number of patients achieving the target maintenance dose (TMD) and sustained unresponsiveness (SU) to allergens (odds ratio [OR] = 2.43 (anti-mouse CD8a 2.43 antibody); 95% CI: 1.33?4.44; p = 0.004; I2 = 35%, and OR = 6.77; 95% CI: 2.10?21.80; p = 0.001; I2 = 36%, respectively). ...The monoclonal anti-IgE antibody (omalizumab) and AIT have complementary actions. ...However, no consensus has been reached on whether their combination could exert superior efficacy and safety. ...Allergen immunotherapy (AIT)-associated adverse events (AEs) limit its usage in the management of allergic diseases. ...The MEDLINE/PubMed, Embase, Scopus and Cochrane Library databases were searched to identify randomized control trials (RCTs) reporting the outcomes of omalizumab combined with AIT (omalizumab + AIT) versus AIT alone.
Tags: anti-mouse CD8a 2.43 antibody; anti-mouse CD8a 2.43 in vivo

For more references about anti-mouse CD8a antibody (2.43) please contact our scientific support team with message@sydlabs.com.

In Vivo Grade Recombinant Anti-Mouse CD8a Monoclonal Antibodies (Clone 2.43):
In Vivo Grade Recombinant Anti-Mouse CD8a Mouse IgG2a Monoclonal Antibody
In Vivo Grade Recombinant Anti-Mouse CD8a Mouse Fab Fragment
In Vivo Grade Recombinant Anti-Mouse CD8a Rat IgG2b Monoclonal Antibody

Syd Labs provides the following recombinant anti-human CD8a monoclonal antibodies:
In vivo grade recombinant anti-human CD8a antibodies (clone OKT8)
Recombinant anti-human CD8a antibodies (clone OKT8) for flow cytometry

Syd Labs provides the following recombinant anti-mouse CD8a monoclonal antibodies:
In vivo grade recombinant anti-mouse CD8a antibodies (clone 2.43)
In vivo grade recombinant anti-mouse CD8a antibodies (clone YTS 169.4)
In vivo grade recombinant anti-mouse CD8a antibodies (clone YTS 105.18)

Syd Labs provides the following recombinant anti-mouse CD8b monoclonal antibodies:
In vivo grade recombinant anti-mouse CD8b antibodies (clone YTS 156.7)

Related Links

See our Privacy Policy